Food and Drug Administration Approved The Cure For Severe Eczema Whith A Hefty Price [VIDEO]
The Food and Drug Administration approved the cure for eczema with a $37,000 price tag per year. Dupixent is said to be ideal for patients who suffer from the skin condition for years without relief.
The drugs for severe eczema, which passed two trials last year, finally got a go signal for mass production from the FDA. Dupixent is said to be effective in alleviating the condition, it does, however, come with a huge price tag, according to the New York Times.
Despite the $37,000/year price tag, it was explained that the medication is still a bit lower compared to other biologic drugs used to treat various skin conditions. Two of the biggest drug makers, Sanofi and Regeneron Pharmaceuticals, were the brains behind the formulation of Dupixent. Both companies made it a point to negotiate with health insurers in terms of coming up with the medicine's cost.
Dr. Leonard S. Schleifer, the chief executive of Regeneron, opened up about their concerns in regards to Donald Trump's decision in allowing drug companies to task over their costly products. Schleifer highlighted that the newly approved drug is way cheaper compared to other skin disease products namely Humira and Enbre which costs around $50,000.
"Things have really deteriorated in our industry," Dr. Leonard S. Schleifer, said during an interview. "There's so much concern over drug pricing that there's an enormous amount of finger-pointing that is going on that's counterproductive. It isn't necessarily incentivizing the right behavior."
Health care providers were quite pleased with the announcement that the Food and Drug Administration approved the cure for eczema. Skin care specialists gave out positive insights in regards to the drug where most said that Dupixent works effectively with minimal serious side effects, as mentioned in the USA Today.
"I always say that atopic dermatitis doesn't kill you, it just ruins your life," Dr. Elaine Siegfried, a professor of pediatrics and dermatology at the St. Louis University School of Medicine stated when she shared her insights regarding the medication. "Dupixent appears to work well, with few serious side effects. It is groundbreaking."